Buprenorphine Formulations and Clinical Challenges in Prescribing Buprenorphine
Participants bring up for discussion questions pertaining to the prescribing and implementation of buprenorphine therapy. An update on the FDA's approval of new formations of buprenorphine for both opioid use disorders and pain is provided.
ASAM and/or CSAM Members: Free
You must register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and choose your purchase option (member/non-member) and click "Add to Cart."
Physicians with a basic understanding of buprenorphine prescribing.
Dr. Torrington's work combines of clinical research, community outreach, education and the practice of medicine. He has over a decade of clinical research. Dr. Torrington serves the community by directly providing care to those without financial means and as the founder and primary addiction specialist of the End Dependence-Common Ground free clinic. Dr. Torrington maintains a private practice specializing in the management of difficult addiction and pain disorders.
- Current speaker Orexo pharmaceuticals
- Current speaker and consultant, BDSI pharmaceuticals
- Current consultant, Braeburn Pharmaceuticals
- Current speaker and consultant, Endo Pharmaceuticals
- 1.00 Attendance
- 1.00 AMA Category 1
Apply a knowledge of the advantages and disadvantages of new buprenorphine formulations.